D Tazhdinov

D Tazhdinov

Auto-generated profile, based on publicly available information

D Tazhdinov

“Mediterra” Center of Modern Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2025 in BULLETIN OF SURGERY OF KAZAKHSTAN
Verified
Journal Article
Closed access
AKA Karabaeva
A Karabaeva
DTD Tazhdinov
D Tazhdinov
SKS Kaniyev
S Kaniyev
IMI Mausymbayeva
I Mausymbayeva
AMA Medetbayeva
A Medetbayeva
IAI Abduzhalilov
I Abduzhalilov
Background: This study evaluated the cardioprotective effect of spironolactone in Wistar rats subjected to 5/6 nephrectomy. Materials and Methods: Chronic kidney insufficiency was induced in Wistar rats via 5/6 nephrectomy. Animals were assigned to three groups: Group 1 — Chronic kidney insufficiency rats treated with spironolactone (0.2 mg/day), Group 2 — Chronic kidney insufficiency rats without treatment, and Group 3 — sham-operated controls. Before euthanasia, mean arterial pressure, heart rate, and 24-hour urine output were recorded. Plasma was analyzed for aldosterone, urea, creatinine, electrolytes, and total protein. The myocardial hypertrophy index was used to assess cardiac changes. Results: Heart rate did not differ significantly among groups. Mean arterial pressure was significantly higher in both Chronic kidney insufficiency groups than in controls (151.3 ± 2.7 mmHg in Group 1, 151.4 ± 2.3 mmHg in Group 2, vs. 121.15 ± 1.8 mmHg in controls, p0.05), whereas in Group 2 it was significantly greater (2.8 ± 0.11, p<0.05). Histological analysis revealed no arteriole wall thickening or connective tissue increase in Groups 1 and 3, while Group 2 showed pronounced arteriole wall thickening. Conclusion: Spironolactone-mediated aldosterone receptor blockade exerts a cardioprotective effect in Wistar rats with Chronic kidney insufficiency induced by 5/6 nephrectomy, independent of systemic Mean systemic arterial pressure changes.

31 December 2025 in BULLETIN OF SURGERY OF KAZAKHSTAN
Verified
Journal Article
Closed access
AKA Karabaeva
A Karabaeva
DTD Tazhdinov
D Tazhdinov
GSG Saduakassova
G Saduakassova
III Ibragimova
I Ibragimova
NYN Yesenbayeva
N Yesenbayeva
NJN Jainakbayev
N Jainakbayev
Background: The study aimed to evaluate myocardial status in patients with chronic kidney disease stages III–V and assess the effect of spironolactone in dialysis patients. Materials and Methods: A total of 46 patients with chronic kidney disease stages III–IV and 83 with stage V on maintenance hemodialysis were examined. Thirty-eight hemodialysis patients received spironolactone 25 mg/day for 6 months. Echocardiography was used to assess left ventricular dimensions, myocardial mass and relative wall thickness. Left ventricular hypertrophy was defined as left ventricular mass index ≥125 g/m² in men and ≥110 g/m² in women; relative wall thickness ≥0.45 was considered increased. Results: In spironolactone-treated patients (Group 1), left atrial diameter decreased from 4.58 ± 0.11 cm to 4.40 ± 0.11 cm; end-diastolic diameter from 4.15 ± 0.13 cm to 3.94 ± 0.17 cm; posterior wall thickness from 1.29 ± 0.03 cm to 1.23 ± 0.04 cm; Left ventricular myocardial mass from 238.46 ± 19.11 g to 206.18 ± 21.45 g; and Left ventricular mass index from 132.2 ± 10.81 g/m² to 113.32 ± 11.75 g/m². In untreated patients (Group 2), parameters showed minimal change: left atrial diameter 4.03 ± 0.11 cm to 3.90 ± 0.09 cm; Left ventricular myocardial mass 293.39 ± 17.13 g to 291.52 ± 15.43 g; Left ventricular mass index 173.57 ± 10.47 g/m² to 176.94 ± 10.06 g/m². Conclusion: In anuric hemodialysis patients, spironolactone 25 mg/day significantly reduced left ventricular posterior wall thickness, myocardial mass and volume, and left atrial size, indicating a cardioprotective effect.